MASH: Natural History , Life Style and Large Real World Data (2)

Nov 10 2025
Convention Center: Ballroom B, Level 3
5:00 PM - 6:30 PM

World Class Speakers

Zobair M Younossi, MD, MPH, FAASLD
Abstract Presenter

Zobair M Younossi, MD, MPH, FAASLD
Robert M Wilechansky, MD
Abstract Presenter

Robert M Wilechansky, MD

Oregon Health & Science University
Rohit Loomba, MD, MHSc, FAASLD
Abstract Presenter

Rohit Loomba, MD, MHSc, FAASLD

University of California, San Diego
Rotonya M. Carr, MD, FACP, FAASLD
Moderator

Rotonya M. Carr, MD, FACP, FAASLD

University of Washington
Rohit Loomba, MD, MHSc, FAASLD
Moderator

Rohit Loomba, MD, MHSc, FAASLD

University of California, San Diego

Description

Abstract Parallel sessions feature oral presentations from the authors of highly-rated abstracts submitted for presentation at The Liver Meeting.

Journey Maps

Presentations

5:00 PM - 5:15 PM
Aug 05 2026
Convention Center - Ballroom B, Level 3

Subtyping Metabolic Dysfunction-Associated Steatotic Liver Disease using Electronic Health Record-Linked Genomic Cohorts Reveals Diverse Etiologies and Progression

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
MASLD
5:15 PM - 5:30 PM
Aug 05 2026
Convention Center - Ballroom B, Level 3

HSD17B13 rs72613567 variant is associated with histological progression and regression in MASLD and it also significantly modifies the effect of BMI change on liver histology

Robert M Wilechansky, MD , Abstract Presenter
MASLD
5:30 PM - 5:45 PM
Aug 05 2026
Convention Center - Ballroom B, Level 3

The usefulness of repeating LSM by VCTE for selecting MASLD patients for pharmacological treatment: results in a large real-world cohort of patients  

Rohit Loomba, MD, MHSc, FAASLD , Abstract Presenter
MASLD
5:45 PM - 6:00 PM
Aug 05 2026
Convention Center - Ballroom B, Level 3

Protective Factors Against Liver Disease Development in Type 2 Diabetes: A Prospective Study Integrating Longitudinal MRI/MRE Imaging and Stable Isotope Tracing

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
MASLD
6:00 PM - 6:15 PM
Aug 05 2026
Convention Center - Ballroom B, Level 3

Improvement In Health-Related Quality of Life After Treatment with Resmetirom in Cirrhotic and Non-Cirrhotic Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease: Data From MAESTRO‑NAFLD

Zobair M Younossi, MD, MPH, FAASLD , Abstract Presenter
MASLD
6:15 PM - 6:30 PM
Aug 05 2026
Convention Center - Ballroom B, Level 3

Relationship of Diurnal Eating Behaviors and Incident MASLD and Cirrhosis in a Pooled Analysis of Three Large Prospective Cohorts

Robert M Wilechansky, MD , Abstract Presenter
MASLD

Objectives

  • Analyze findings from large real-world data sets to identify trends, gaps, and implications for patient management and future research.
  • Describe the natural history and progression patterns of MASH, including risk factors for fibrosis advancement and liver-related outcomes